Treatment approaches to prosthetic joint infections: results of an Emerging Infections Network survey

Diagnostic Microbiology and Infectious Disease

Volumn 66, Issue 1, 2010, Pages 16-23

  Johannsson, Birgir ^a   Taylor, James ^a   Clark, Charles R ^a   Shamsuddin, Hala ^b   Beekmann, Susan E ^a   Polgreen, Philip ^a,c  

^a UNIVERSITY OF IOWA   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Antibiotic impregnated materials; Diagnosis; Infection; Prosthetic joint; Toxicity; Treatment

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BONE CEMENT; CEPHALOSPORIN; TOBRAMYCIN; VANCOMYCIN;

ARTHROPLASTY; ARTICLE; CONSULTATION; DEVICE REMOVAL; DIAGNOSTIC TEST; DRUG HYPERSENSITIVITY; HEALTH SURVEY; HUMAN; INFECTIOUS ARTHRITIS; KIDNEY FAILURE; MATERIAL COATING; NEPHROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; PROSTHESIS INFECTION; RASH; REIMPLANTATION; SKIN MANIFESTATION; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION;

EID: 71049137668     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.08.016     Document Type: Article

References (41)

1. Aboltins C.A., Page M.A., Buising K.L., Jenney A.W., Daffy J.R., Choong P.F., and Stanley P.A. Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid. Clin. Microbiol. Infect. 13 (2007) 586-591
2. Anagnostakos K., Furst O., and Kelm J. Antibiotic-impregnated PMMA hip spacers: current status. Acta Orthop. 77 (2006) 628-637
3. Betsch B.Y., Eggli S., Siebenrock K.A., Tauber M.G., and Muhlemann K. Treatment of joint prosthesis infection in accordance with current recommendations improves outcome. Clin. Infect. Dis. 46 (2008) 1221-1226
4. Bridgens J., Davies S., Tilley L., Norman P., and Stockley I. Orthopaedic bone cement: do we know what we are using?. J. Bone Joint Surg. Br. 90 (2008) 643-647
5. Curtis J.M., Sternhagen V., and Batts D. Acute renal failure after placement of tobramycin-impregnated bone cement in an infected total knee arthroplasty. Pharmacotherapy 25 (2005) 876-880
6. Deirmengian C., Greenbaum J., Lotke P.A., Booth Jr. R.E., and Lonner J.H. Limited success with open debridement and retention of components in the treatment of acute Staphylococcus aureus infections after total knee arthroplasty. J. Arthroplasty 18 7 Suppl. 1 (2003) 22-26
7. Diekema D.J., Pfaller M.A., Schmitz F.J., Smayevsky J., Bell J., Jones R.N., Beach M., and SENTRY Partcipants Group. Survey of infections due to staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY antimicrobial surveillance program, 1997-1999. Clin. Infect. Dis. 32 Suppl. 2 (2001) S114-S132
8. Disch A.C., Matziolis G., and Perka C. Two-stage operative strategy without local antibiotic treatment for infected hip arthroplasty: clinical and radiological outcome. Arch. Orthop. Trauma Surg. 127 (2007) 691-697
9. Dovas S., Liakopoulos V., Papatheodorou L., Chronopoulou I., Papavasiliou V., Atmatzidis E., Giannopoulou M., Eleftheriadis T., Simopoulou T., Karachalios T., et al. Acute renal failure after antibiotic-impregnated bone cement treatment of an infected total knee arthroplasty. Clin. Nephrol. 69 (2008) 207-212
10. Ghanem E., Parvizi J., Burnett R.S., Sharkey P.F., Keshavarzi N., Aggarwal A., and Barrack R.L. Cell count and differential of aspirated fluid in the diagnosis of infection at the site of total knee arthroplasty. J. Bone Joint Surg. Am. 90 (2008) 1637-1643
11. Haleem A.A., Berry D.J., and Hanssen A.D. Mid-term to long-term followup of two-stage reimplantation for infected total knee arthroplasty. Clin. Orthop. Relat. Res. 428 (2004) 35-39
12. Havelin L.I., Engesaeter L.B., Espehaug B., Furnes O., Lie S.A., and Vollset S.E. The Norwegian arthroplasty register: 11 years and 73,000 arthroplasties. Acta Orthop. Scand. 71 (2000) 337-353
13. Hofmann A.A., Goldberg T.D., Tanner A.M., and Cook T.M. Ten-year experience using an articulating antibiotic cement hip spacer for the treatment of chronically infected total hip. J. Arthroplasty 20 (2005) 874-879
14. Hsieh P.H., Shih C.H., Chang Y.H., Lee M.S., Shih H.N., and Yang W.E. Two-stage revision hip arthroplasty for infection: comparison between the interim use of antibiotic-loaded cement beads and a spacer prosthesis. J. Bone Joint Surg. Am. 86-A (2004) 1989-1997
15. Hsieh P.H., Chen L.H., Chen C.H., Lee M.S., Yang W.E., and Shih C.H. Two-stage revision hip arthroplasty for infection with a custom-made, antibiotic-loaded, cement prosthesis as an interim spacer. J. Trauma 56 (2004) 1247-1252
16. Husted H., and Toftgaard Jensen T. Clinical outcome after treatment of infected primary total knee arthroplasty. Acta Orthop. Belg. 68 (2002) 500-507
17. Kilgus D.J., Howe D.J., and Strang A. Results of periprosthetic hip and knee infections caused by resistant bacteria. Clin. Orthop. Relat. Res. 404 (2002) 116-124
18. Knutson K., Lewold S., Robertsson O., and Lidgren L. The Swedish knee arthroplasty register. A nation-wide study of 30,003 knees 1976-1992. Acta Orthop. Scand. 65 (1994) 375-386
19. Kosters K., van Crevel R., Sturm P.D., Willem Schreurs B., de Waal Malefijt M.C., van Kampen A., and Kullberg B.J. Treatment of knee prosthesis infections: evaluation of 15 patients over a 5-year period. Int. Orthop. (2008) Epub ahead of print (PMID 18704413)
20. Kurtz S., Mowat F., Ong K., Chan N., Lau E., and Halpern M. Prevalence of primary and revision total hip and knee arthroplasty in the United States from 1990 through 2002. J. Bone Joint Surg. Am. 87 (2005) 1487-1497
21. Kurtz S., Ong K., Lau E., Mowat F., and Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J. Bone Joint Surg. Am. 89 (2007) 780-785
22. Kurtz S.M., Lau E., Schmier J., Ong K.L., Zhao K., and Parvizi J. Infection burden for hip and knee arthroplasty in the United States. J. Arthroplasty 23 (2008) 984-991
23. Marculescu C.E., Berbari E.F., Hanssen A.D., Steckelberg J.M., Harmsen S.W., Mandrekar J.N., and Osmon D.R. Outcome of prosthetic joint infections treated with debridement and retention of components. Clin. Infect. Dis. 42 (2006) 471-478
24. McKenna P.B., O'Shea K., and Masterson E.L. Two-stage revision of infected hip arthroplasty using a shortened post-operative course of antibiotics. Arch. Orthop. Trauma. Surg. 129 (2009) 489-494
25. McLaren R.L., McLaren A.C., and Vernon B.L. Generic tobramycin elutes from bone cement faster than proprietary tobramycin. Clin. Orthop. Relat. Res. 466 (2008) 1372-1376
26. McPherson E.J., Woodson C., Holtom P., Roidis N., Shufelt C., and Patzakis M. Periprosthetic total hip infection: outcomes using a staging system. Clin. Orthop. Relat. Res. 403 (2002) 8-15
27. Muller M., Morawietz L., Hasart O., Strube P., Perka C., and Tohtz S. Diagnosis of periprosthetic infection following total hip arthroplasty-evaluation of the diagnostic values of pre- and intraoperative parameters and the associated strategy to preoperatively select patients with a high probability of joint infection. J. Orthop. Surg. 3 (2008) 31
28. Parvizi J., Saleh K.J., Ragland P.S., Pour A.E., and Mont M.A. Efficacy of antibiotic-impregnated cement in total hip replacement. Acta Orthop. 79 (2008) 335-341
29. Patrick B.N., Rivey M.P., and Allington D.R. Acute renal failure associated with vancomycin- and tobramycin-laden cement in total hip arthroplasty. Ann. Pharmacother. 40 (2006) 2037-2042
30. Penner M.J., Masri B.A., and Duncan C.P. Elution characteristics of vancomycin and tobramycin combined in acrylic bone-cement. J. Arthroplasty 11 (1996) 939-944
31. Phillips J.E., Crane T.P., Noy M., Elliott T.S., and Grimer R.J. The incidence of deep prosthetic infections in a specialist orthopaedic hospital: a 15-year prospective survey. J. Bone Joint Surg. Br. 88 (2006) 943-948
32. Puolakka T.J., Pajamaki K.J., Halonen P.J., Pulkkinen P.O., Paavolainen P., and Nevalainen J.K. The Finnish arthroplasty register: report of the hip register. Acta Orthop. Scand. 72 (2001) 433-441
33. Scharfenberger A., Clark M., Lavoie G., O'Connor G., Masson E., and Beaupre L.A. Treatment of an infected total hip replacement with the PROSTALAC system. Part 1: Infection resolution. Can. J. Surg. 50 (2007) 24-28
34. Segawa H., Tsukayama D.T., Kyle R.F., Becker D.A., and Gustilo R.B. Infection after total knee arthroplasty. A retrospective study of the treatment of eighty-one infections. J. Bone Joint Surg. Am. 81 (1999) 1434-1445
35. Springer B.D., Lee G.C., Osmon D., Haidukewych G.J., Hanssen A.D., and Jacofsky D.J. Systemic safety of high-dose antibiotic-loaded cement spacers after resection of an infected total knee arthroplasty. Clin. Orthop. Relat. Res. 427 (2004) 47-51
36. Standards, Practice Guidelines Summary Table [Internet] http://www.idsociety.org/Content.aspx?id=9088. http://www.idsociety.org: Infectious Disease Society of America; c2009 [cited 2009 04/29]. Available from: http://www.idsociety.org/WorkArea/showcontent.aspx?id=13484.
37. Tattevin P., Cremieux A.C., Pottier P., Huten D., and Carbon C. Prosthetic joint infection: when can prosthesis salvage be considered?. Clin. Infect. Dis. 29 (1999) 292-295
38. Trampuz A., Piper K.E., Hanssen A.D., Osmon D.R., Cockerill F.R., Steckelberg J.M., and Patel R. Sonication of explanted prosthetic components in bags for diagnosis of prosthetic joint infection is associated with risk of contamination. J. Clin. Microbiol. 44 (2006) 628-631
39. van Raaij T.M., Visser L.E., Vulto A.G., and Verhaar J.A. Acute renal failure after local gentamicin treatment in an infected total knee arthroplasty. J. Arthroplasty 17 (2002) 948-950
40. Wang C.J., Huang T.W., Wang J.W., and Chen H.S. The often poor clinical outcome of infected total knee arthroplasty. J. Arthroplasty 17 (2002) 608-614
41. Zimmerli W., Widmer A.F., Blatter M., Frei R., and Ochsner P.E. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. foreign-body infection (FBI) study group. JAMA 279 (1998) 1537-1541